Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03751709
Title Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Cedars-Sinai Medical Center
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.